0000000000816207

AUTHOR

Daniele Camboni

showing 1 related works from this author

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

2013

ObjectivesThis study sought to predict the value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE]).BackgroundRisk stratification after TAVI remains challenging. The use of biomarkers in this setting represents an unmet need.MethodsCA125 was measured in 228 patients before and after TAVI. The association with outcomes was assessed using parametric Cox regression and joint modeling for baseline and longitudinal analyses, respectively. CA125 was evaluated as logarithm transforma…

Malemedicine.medical_specialtyCardiac CatheterizationTime FactorsAortic Valve InsufficiencyMyocardial InfarctionKaplan-Meier EstimateRisk AssessmentCA125Interquartile rangeRisk FactorsInternal medicineMedicineHumansMyocardial infarctionLongitudinal StudiesRegistriesStroketranscatheter aortic valve implantationTumor markerAgedProportional Hazards ModelsAged 80 and overHeart FailureHeart Valve Prosthesis ImplantationProportional hazards modelbusiness.industryMembrane ProteinsAortic Valve Stenosismedicine.diseasejoint modelingHospitalizationStrokeLogistic ModelsTreatment OutcomeCardiovascular DiseasesHeart failureCA-125 AntigenMultivariate AnalysisCardiologybiomarkerBiomarker (medicine)FemaleprognosisbusinessCardiology and Cardiovascular MedicineMaceBiomarkersJACC: Cardiovascular Interventions
researchProduct